The recently reported SELECT trial (Semaglutide Effects on Heart Disease and Stroke in
Patients With Overweight or Obesity) 3 tested this hypothesis using the higher-dose …

Progress in the field of obesity may seem to have progressed at a snail's pace, but
tremendous advances have been made during the last few decades in our understanding of …

With the development of newer weight loss agents with more marked effects on body weight,
in some instances approaching the weight-loss effects of bariatric surgery, we may soon …

More than half the world population is expected to be overweight or obese by the year 2035
[1]. Obesity and atherosclerotic cardiovascular disease have always been a fatal …

Overweight or obesity has been independently associated with increased cardiovascular
risk, yet interventional trials of lifestyle or pharmacologic management strategies for …

Cardiovascular disease (CVD) is a major cause of morbidity and mortality. Although it has
been widely appreciated that obesity is a major risk factor for CVD, treatments that produce …

Treatment with the glucagon-like peptide 1 receptor agonist semaglutide, administered
subcutaneously at a dose of 2.4 mg once per week, reduces the risk of major cardiovascular …

• In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or
Obesity trial, the SELECT Investigators tested the hypothesis that the addition of …

Objective This paper describes the baseline characteristics of the Semaglutide Effects on
Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the …

Cardiovascular disease (CVD) is a leading global cause of death, with preventable risk
factors like obesity contributing most to it. Obesity's association with CVD originate from …